Effect of an MG132-Sustained Drug Delivery Capsular Ring on the Inhibition of Posterior Capsule Opacification in a Rabbit Model

• Published in: Journal of ocular pharmacology and therapeutics Vol. 33; no. 2; p. 103
• Main Authors: Bao, Xuan, Hou, Min, Qin, Yingyan, Luo, Furong, Shang, Fu, Wu, Mingxing
• Format: Journal Article
• Language: English
• Published: United States 01.03.2017
• Subjects: Animals; Capsule Opacification - drug therapy; Disease Models, Animal; Drug Delivery Systems; Lactic Acid - administration & dosage; Lactic Acid - pharmacology; Leupeptins - administration & dosage; Leupeptins - pharmacology; Polyglycolic Acid - administration & dosage; Polyglycolic Acid - pharmacology; Posterior Capsule of the Lens - drug effects; Rabbits; MG132; epithelial–mesenchymal transition; posterior capsule opacification; sustained drug delivery system; capsular tension ring
• ISSN: 1557-7732
• DOI: 10.1089/jop.2016.0163

To design an MG132-sustained drug delivery capsular ring (SDDCR) and investigate its effect on the inhibition of posterior capsule opacification (PCO) in a rabbit model. The SDDCRs were prepared by forming a slice of film made by the mixture of poly lactic-co-glycolic acid (PLGA) and MG132 on the surface of capsular tension rings (CTRs). The drug-loading capacity, entrapment efficiency, and in vitro release of the drug-containing film were detected. Eighteen New Zealand white rabbits were operated with phacoemulsification and MG132-SDDCRs/PLGA-CTRs/CTRs implantation in the single eye. The images of the anterior segments were acquired at certain days, and the epithelial-mesenchymal transition (EMT) markers were detected by western blot and immunofluorescence. The drug-loading capacity and entrapment efficiency of MG132-SDDCRs were 1.15% ± 0.04% and 66.16% ± 0.027%, respectively, and the drug released well within a month. The PCO degree of the MG132-SDDCR group was significantly lower than the other groups. The expression of alpha-smooth muscle actin, fibronectin, vimentin, and collagen-I was lower, and the expression of E-cadherin (E-cad) was higher in the MG132-SDDCR group than the other groups. MG132-SDDCRs could be established successfully. The PCO process was prevented, and the expression of EMT markers was inhibited by the implantation of MG132-SDDCRs, indicating that this could be a potential treatment against PCO.